Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

COALIZAO ACTION
 
NCT04394377
RCTanticoagulant, curative dosecontrolCOVID 19 hospitalizedsome concern
311/304 inconclusive
    COALIZAO ACTION
     
    NCT04394377
    RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID 19 hospitalizedsome concern
    311/304 inconclusive

      COVID-19 mild to moderate meta-analysis

      ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
       
      NCT02735707
      RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
      1190/1054 conclusif
      • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      atypical endpoints without correspondence with those of the others trials
      ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
       
      NCT02735707
      RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
      1190/1054 conclusif
      • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      atypical endpoints without correspondence with those of the others trials

      COVID-19 severe or critically meta-analysis

      COVID-PACT RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
      191/191 suggested
      • suggested 44 % decrease in Major thrombotic events or death (PE) with a moderate degree of certainty due to some concern in risk of bias
      REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
       
      NCT02735707
      RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
      591/616 inconclusive
      • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
      REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
       
      NCT02735707
      RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
      591/616 inconclusive
      • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
      1 study excluded by filtering options (0 RCT / 1 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).